A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recently, we reported oligoadenylate synthetase 1 (OAS1) contributed to the risk of Alzheimer’s disease, by its enrichment in transcriptional networks expressed by microglia. However, the function of OAS1 within microglia was not known. Using genotyping from 1313 individuals with sporadic Alzheimer’s disease and 1234 control individuals, we confirm the OAS1 variant, rs1131454, is associated with increased risk for Alzheimer’s disease. The same OAS1 locus has been recently associated with severe coronavirus disease 2019 (COVID-19) outcomes, linking risk for both diseases. The single nucleotide polymorphisms rs1131454(A) and rs4766676(T) are associated with Alzheimer’s disease, and rs10735079(A) and rs6489867(T) are associated with severe COVID-19, where the risk alleles are linked with decreased OAS1 expression. Analysing single-cell RNA-sequencing data of myeloid cells from Alzheimer’s disease and COVID-19 patients, we identify co-expression networks containing interferon (IFN)-responsive genes, including OAS1, which are significantly upregulated with age and both diseases. In human induced pluripotent stem cell-derived microglia with lowered OAS1 expression, we show exaggerated production of TNF-α with IFN-γ stimulation, indicating OAS1 is required to limit the pro-inflammatory response of myeloid cells. Collectively, our data support a link between genetic risk for Alzheimer’s disease and susceptibility to critical illness with COVID-19 centred on OAS1, a finding with potential implications for future treatments of Alzheimer’s disease and COVID-19, and development of biomarkers to track disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a genetic perspective, some genes such as APOE4 and oligoadenylate synthetase 1 (OAS1) play important roles in susceptibility to both COVID-19 and AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [606]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and linked with a pro-inflammatory response via STAT/NF-kappaB in microglia/macrophages when experimentally downregulated [60].”
From Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some variants in the interferon-responsive gene OAS1 may lower its expression and potentially increase the likelihood of AD and severe COVID-19, through excessive release of pro-inflammatory signals in myeloid cells such as microglia and macrophages, further leading to cell death.606”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [606]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“Data were normalized using DeSeq2’s estimatesizefactors function and transformed by log2(normalized counts + 1).(71) Genes with an average detection level 51.”
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“dataset was removed using Limma’s RemoveBatchEffect function, preserving the effect of age using the mod argument.(72) Batch information was not available for data from Friedman et al.”
MethodPLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089 · cited 2×
“regression correcting for the covariates with the statistical analysis program PLINK.(59) SNPs in the locus containing OAS1 associated with Alzheimer’s disease,(12,60) and COVID-19,(32) were illustrated with LocusZoom.”
MethodWGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038 · cited 1×
“Gene expression analyses were performed by following the GeNorm method.(79,80)”
MethodA global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971 · cited 1×
“TNF-a with C1Q complement (which also shows elevated expression in our human iPSC-derived microglia system in response to OAS1 knockdown), has been shown to induce the activation of reactive astrocytes, which contribute to synaptic damage, phagocytosis, and death of neurons and oligodendrocytes.(105) Previously, we an…”
BackgroundTrapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N. J., Livak, K. J., Mikkelsen, T. S., & Rinn, J. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2859 · Cited by 7,314
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders
Huang, Y., Liu, B., Sinha, S. C., Amin, S., & Gan, L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00672-x · Cited by 164
“These enzymes possess architecture similarity to another NTase, 2 ′ 5 ′ -oligoadenylate synthase (OAS1) [95], which is a genetic risk factor for AD and severe COVID-19 outcomes [96], and produce diverse cyclic and oligonucleotides.”
BackgroundInborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children
Lee, D., Le Pen, J., Yatim, A., Dong, B., Aquino, Y., Ogishi, M., Pescarmona, R., Talouarn, E., Rinchai, D., Zhang, P., et al. (2023) · Science · doi:10.1126/science.abo3627 · Cited by 158
“Nevertheless, genome-wide association studies have suggested that common variants in the vicinity of OAS1 may be weakly associated with COVID-19 severity ( 10 , 11 , 53 , 76 – 79 ).”
Kurki, S. N., Kantonen, J., Kaivola, K., Hokkanen, L., Mäyränpää, M. I., Puttonen, H., FinnGen, Martola, J., Pöyhönen, M., Kero, M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01302-7 · Cited by 91
Stadio, A. D., Brenner, M. J., Luca, P. D., Albanese, M., D’Ascanio, L., Ralli, M., Roccamatisi, D., Cingolani, C., Vitelli, F., Camaioni, A., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12020154 · Cited by 80
“Because AD is more prevalent in women than men, [20] and SARS-CoV-2 inflammation can spread from the olfactory bulbs to other parts of the brain [21] increasing the neuroinflammation rate, we hypothize that anosmia may portend future neuro-degenerative neurological disease in predisposed subjects [18,22], as for examp…”
BackgroundYang, C., Fagan, A. M., Perrin, R. J., Rhinn, H., Harari, O., & Cruchaga, C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01140-9 · Cited by 53
“[38] reported that OAS1 is required to limit the proinflammatory response of human induced pluripotent stem cell-derived microglia.”
BackgroundResultWang, Y., Huang, Z., Yu, X. H., Wan, W., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1015882 · Cited by 58
“Another study found a link between OAS1 genetic risk for frontiersin.org Alzheimer’s disease and susceptibility to critical illness with COVID-19 (38, 39).”
BackgroundInfluentialHuang, P., Zhang, L., Tan, Y., & Chen, S. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00337-1 · Cited by 63
“Their study identified single nucleotide polymorphisms of the OAS1 gene to be associated with both increased risk of AD and predisposition to severe COVID-19 [207].”
BackgroundLang, R., Li, H., Luo, X., Liu, C., Zhang, Y., Guo, S., Xu, J., Bao, C., Dong, W., & Yu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1008072 · Cited by 59
Type-I Interferons in Alzheimer's Disease and Other Tauopathies
Sanford, S. A. I., & McEwan, W. A. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.949340 · Cited by 39
“This includes OAS1, a cytosolic RNA sensor responsible for degrading cellular and viral RNAs (Magusali et al., 2021).”
BackgroundVilla, C., Rivellini, E., Lavitrano, M., & Combi, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010029 · Cited by 35
Cholinergic blockade of neuroinflammation: from tissue to RNA regulators
Zorbaz, T., Madrer, N., & Soreq, H. (2022) · Neuronal Signaling · doi:10.1042/ns20210035 · Cited by 30
Chung, S. J., Chang, Y., Jeon, J., Shin, J. I., Song, T., & Kim, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220031 · Cited by 28
“A genetic variant 323 of oligoadenylate synthetase 1, known to be associ324 ated with severe outcome with COVID-19 infection, 325 is also associated with an increased risk for AD [31].”
The viral hypothesis in Alzheimer’s disease: SARS-CoV-2 on the cusp
Liu, N., Jiang, X., & Li, H. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1129640 · Cited by 31
Neurocognitive screening in patients following SARS-CoV-2 infection: tools for triage
Blackmon, K., Day, G. S., Powers, H. R., Bosch, W., Prabhakaran, D., Woolston, D. J., & Pedraza, O. (2022) · BMC Neurology · doi:10.1186/s12883-022-02817-9 · Cited by 24
“Contributions from aberrant acute and chronic inflammation are also expected [11 31 32], with possible unmasking or exacerbation of incipient neurodegenerative disease processes [31], or shared pro-inflammatory risk factors for both Alzheimer’s disease and severe COVID-19 [33].”
BackgroundGemmati, D., Longo, G., Gallo, I., Silva, J. A., Secchiero, P., Zauli, G., Hanau, S., Passaro, A., Pellegatti, P., Pizzicotti, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1028081 · Cited by 24
“APOE Ɛ4 allele has been particularly investigated in neurodegenerative and cognitive impairment diseases, and indeed, severe COVID-19 and Alzheimer’s disease share common genetic and metabolic pathways via the OAS1 gene and many risk factors strongly overlap (Tisato et al., 2018; Gemmati et al., 2020; Magusali et al.,…”
BackgroundSchreiber, C. S., Wiesweg, I., Stanelle‐Bertram, S., Beck, S., Kouassi, N. M., Schaumburg, B., Gabriel, G., Richter, F., & Käufer, C. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105191 · Cited by 21
Vavougios, G. D., Mavridis, T., Artemiadis, A., Krogfelt, K. A., & Hadjigeorgiou, G. M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166430 · Cited by 21
Yang, R., Du, Y., Zhang, M., Liu, Y., Feng, H., Liu, R., Yang, B., Xiao, J., He, P., & Niu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1249731 · Cited by 25
Unravelling the connection between COVID-19 and Alzheimer’s disease: a comprehensive review
Shajahan, S. R., Kumar, S., & Ramli, M. D. C. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1274452 · Cited by 27
Pomilio, A. B., Vitale, A. A., & Lazarowski, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666221003101548 · Cited by 20
Amadoro, G., Latina, V., Stigliano, E., & Micera, A. (2023) · Cells · doi:10.3390/cells12222601 · Cited by 22
Chaudhuri, S., Cho, M., Stumpff, J., Bice, P. J., İş, Ö., Ertekin‐Taner, N., Saykin, A. J., & Nho, K. T. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00798-0 · Cited by 22
“In addition, differentially expressed genes (DEGs) common to AD, COVID-19 patients, and SARS-CoV-2-infected cells have been found to be significantly involved in immune responses, particularly in the modulation of cytokine storms [165, 166].”
Delgado‐Wicke, P., de Córdoba‐Oñate, S. F., Roy‐Vallejo, E., Alegría‐Carrasco, E., Rodríguez-Serrano, D. A., Lamana, A., Montes, N. G., Nicolao-Gómez, A., Carracedo-Rodríguez, R., Marcos‐Jiménez, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71476-2 · Cited by 20
“We found the missense variant rs1131454-AA associated with disease severity, in agreement with previous reports relating this variant to COVID-19 hospitalization 54,55 or increased risk for Alzheimer’s disease 56 .”
ResultThe Microbiome and Mental Health Across the Lifespan
Dickerson, F., Dilmore, A. H., Godoy‐Vitorino, F., Nguyen, T. T., Paulus, M. P., Pinto‐Tomás, A. A., Moya-Roman, C., Zúñiga-Chaves, I., Severance, E. G., & Jeste, D. V. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_384 · Cited by 18
The role of interferon signaling in neurodegeneration and neuropsychiatric disorders
Sirkis, D. W., Oddi, A. P., Jonson, C., Bonham, L. W., Hoang, P. T., & Yokoyama, J. S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1480438 · Cited by 17
“Beyond studies of mouse models and post-mortem AD brain tissue, recent integrative analyses of human genetic data and microglial transcriptomic data have suggested that variation in OAS1 , an established IFN response gene, may modify risk for AD (14, 15).”
BackgroundRecent insights into viral infections as a trigger and accelerator in alzheimer's disease
Vlieger, L. D., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103340 · Cited by 17
“showed that single nucleotide polymorphisms in the OAS1 gene increase the risk of AD development and that related variants of this gene are also associated with the severity of COVID-19.(146) The OAS1 gene is expressed in microglia and seems to be involved in limiting proinflammatory responses.”
InfluentialCOVID ‐19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis
Zhang, H., & Zhou, Z. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51688 · Cited by 20
“In addition, a recent genotyping analysis revealed an SNP in oligoadenylate synthetase 1 (OAS1) linked to AD in the same locus that predisposes to COVID-19-related critical illness.(52) The biological mechanisms underlying the association between COVID-19 and the risk of AD remain to be disclosed in longitudinal and m…”
BackgroundKim, J. H., Chang, I. B., Kim, Y. H., Min, C., Yoo, D. M., & Choi, H. G. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.821235 · Cited by 16
Wei, Z. D., Liang, K., & Shetty, A. K. (2023) · Aging and Disease · doi:10.14336/ad.2023.0312 · Cited by 18
Human genetic basis of severe or critical illness in COVID-19
Ji, X.-S., Chen, B., Ze, B., & Zhou, W. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.963239 · Cited by 14
“In addition,OAS1 was identified as a putative new risk gene for Alzheimer’s disease, and 4 alleles within OAS1 gene were identified to contribute to both the high incidence of Alzheimer’s disease and critical illness of COVID-19 (Magusali et al., 2021).”
BackgroundThe Adverse Outcome Pathway Framework Applied to Neurological Symptoms of COVID-19
Högberg, H. T., Lam, A., Ohayon, E. L., Shahbaz, M. A., Clerbaux, L., Bal‐Price, A., Coecke, S., Concha, R., Bernardi, F., Edrosa, E., et al. (2022) · Cells · doi:10.3390/cells11213411 · Cited by 17
“to both AD and COVID-19 [146], yet further studies are needed to fully address the details”
BackgroundPan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types
Jiang, S., Deng, X., Luo, M., Zhou, L., Chai, J., Tian, C., Yan, Y., & Luo, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1207081 · Cited by 13
“It is noteworthy that the latest studies show that OAS1 is associated with COVID-19 incidence (12, 13), so OAS1 may have certain application prospect for clinical evaluations.”
BackgroundThe relationship of early- and late-onset Alzheimer’s disease genes with COVID-19
Şirin, S., Dolanbay, S. N., & Aslım, B. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02499-0 · Cited by 14
Gokul, A., Arumugam, T., & Ramsuran, V. (2023) · Genes · doi:10.3390/genes14020527 · Cited by 16
Sarker, B., Rahaman, M. M., Islam, M. A., Alamin, M. H., Husain, M. M., Ferdousi, F., Ahsan, M. A., & Mollah, M. N. H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281981 · Cited by 14
Insights for Alzheimer's disease pharmacotherapy and current clinical trials
do Nascimento, A. L. C. S., Fernandes, R. P., Carvalho, A. C. S., Frigieri, I., Alves, R. C., & Chorilli, M. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105401 · Cited by 14
Crook, H., Ramírez, A., Hosseini, A. A., Vavougios, G. D., Lehmann, C., Bruchfeld, J., Schneider, A., d’Avossa, G., Re, V. L., Salmoiraghi, A., et al. (2023) · Brain Connectivity · doi:10.1089/brain.2022.0058 · Cited by 12
“…feed forward activation of microglia would be modulated by the operational status of enhancers ( Vavou-gios et al, 2021b) or abrogators (Magusali et al, 2021) of neuroinflammation defined by both host genetics and epige-netics, as well as SARS-CoV-2’s differential modulation of IFN-I…”
Vavougios, G. D., Tseriotis, V., Liampas, A., Mavridis, T., de Erausquin, G. A., & Hadjigeorgiou, G. M. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1352118 · Cited by 13
Coburn, M., Eskandari‐Sedighi, G., Hasselmann, J., England, W., Shabestari, S. K., Mansour, K., McQuade, A., Mgerian, M., Chadarevian, J. P., Tu, C. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70930 · Cited by 15
Structural basis for OAS2 regulation and its antiviral function
Merold, V., Bekere, I., Kretschmer, S., Schnell, A. F., Kmieć, D., Sivarajan, R., Lammens, K., Liu, R., Mergner, J., Teppert, J., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.05.001 · Cited by 16
Kostev, K., Geßler, N., Wohlmuth, P., Arnold, D., Bein, B., Bohlken, J., Herrlinger, K. R., Jacob, L., Koyanagi, A., Nowak, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220918 · Cited by 10
“Interestingly, it has been demonstrated that the genes associated with Alzheimer’s disease (APOE and BIN1) in patients who are at risk of developing the condition or who already suffer from it are responsible for COVID-19 severity and even death in these patients [28, 29].”
The Two-Way Route between Delirium Disorder and Dementia: Insights from COVID-19
Bommarito, G., Garibotto, V., Frisoni, G. B., Assal, F., Lalive, P. H., & Allali, G. (2022) · Neurodegenerative Diseases · doi:10.1159/000530566 · Cited by 11
“Other genetic crossroads have been found between AD and COVID-19 severity [105], and though not speci fi cally investigated as predictors for encephalopathy yet, they could offer future roads to cover.”
Vavougios, G. D., de Erausquin, G. A., & Snyder, H. M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1063298 · Cited by 11
Cataldo, A., Criscuolo, S., Benedetto, E. D., Masciullo, A., Pesola, M., & Schiavoni, R. (2023) · Bioengineering · doi:10.3390/bioengineering10040435 · Cited by 11
Emerging Models to Study Human Microglia In vitro
Jäntti, H., Kistemaker, L., Buonfiglioli, A., de Witte, L. D., Malm, T., & Hol, E. M. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_30 · Cited by 8
Alzheimer’s Disease and SARS-CoV-2: Pathophysiological Analysis and Social Context
Ortíz, G. G., Velázquez-Brizuela, I. E., Ortiz-Velázquez, G. E., Ocampo-Alfaro, M. J., Flores, J. S., Delgado-Lara, D. L. C., & Torres-Sánchez, E. D. (2022) · Brain Sciences · doi:10.3390/brainsci12101405 · Cited by 9
“It is important to note that SARS-CoV-2 invasion in neuronal tissues is regulated by the binding of the spike protein to ACE2 receptors from neurons, glial cells, and capillary endothelium [33].”
BackgroundInfluentialTranscriptomic Analyses of Exercise Training in Alzheimer’s Disease Cerebral Cortex
Widjaya, M. A., Cheng, Y., Kuo, Y., Liu, C.-H., Cheng, W., & Lee, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221139 · Cited by 8
“Oas1a contributes to AD progression by regulating the interferon molecular pathway in microglia [55].”
Aksnes, M., Aass, H. C. D., Tiiman, A., Terenius, L. Y., Bogdanović, N., Vukojević, V. B., & Knapskog, A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215504 · Cited by 10
“Indeed, the OAS1 gene, which controls proinflammatory responses of peripheral myeloid cells, has recently been linked to both AD and critical illness with coronavirus disease 2019 (COVID-19) [40].”
BackgroundViruses - a major cause of amyloid deposition in the brain
Fülöp, T., Ramassamy, C., Lévesque, S., Frost, E. H., Laurent, B., Lacombe, G., Khalil, A., Larbi, A., Hirokawa, K., Desroches, M., et al. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2244162 · Cited by 8
The human microglia responsome: a resource for microglia states in health and disease
Snijders, G. J. L., Lopes, K. D. P., Sneeboer, M. A. M., Muller, B. Z., Gigase, F. A. J., D’Urso, D., Vialle, R. A., Missall, R. D., Kübler, R., Raj, T., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106095 · Cited by 9
CASA: a comprehensive database resource for the COVID-19 Alternative Splicing Atlas
Chen, Y., Wang, G., Li, J., Xia, L., Zhu, L., Li, W., Luo, Q., Liao, Y., Lin, Y., Bi, L., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03699-8 · Cited by 8
“This result from CASA is consistent with previous findings that OAS1 splicing pattern was associated with COVID-19 susceptibility and severity [8, 30– 34], indicating CASA is a reliable and accurate database for AS-related research.”
ResultHoltman, I. R., Glass, C. K., & Nott, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_29 · Cited by 7
Wan, J., van Ouwerkerk, A. F., Mouren, J.-C., Heredia, C., Pradel, L. C., Ballester, B., Andrau, J., & Spicuglia, S. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1270 · Cited by 8
“In particular, the expression of OAS1 / 2 / 3 has been associated with severe COVID-9 ( 105 ,120–122 ).”
Li, S., Sun, J., Li, H., Han, Z., Wang, T., Gao, S., Zhu, P., Chen, Y., Yan, P., Wang, M., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03006-z · Cited by 6
Ayyubova, G., Bablu, F. E., Rahimli, N., Aghayeva, L., Springer, E. M., Alghenaim, F., & Suzuki, Y. J. (2026) · Antioxidants · doi:10.3390/antiox15010066 · Cited by 9
OAS1 rs1131454 genetic variant is associated with Alzheimer’s disease: an epidemiological analysis
Padhi, S., Sarangi, S., Nayak, N., Pati, A., & Panda, A. K. (2022) · Brain · doi:10.1093/brain/awac132 · Cited by 6
SARS-CoV-2 Neuroinvasion, Inflammatory Neurodegeneration and Alzheimer's Disease
Zhao, Y., & Lukiw, W. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.937961 · Cited by 6
Investigational drugs for the treatment of olfactory dysfunction
Stadio, A. D., Severini, C., Colizza, A., VINCENTIIS, M. D., & Mantia, I. L. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113054 · Cited by 6
SARS-CoV-2 Attacks in the Brain: Focus on the Sialome
Wielgat, P., Narejko, K., & Car, H. (2022) · Cells · doi:10.3390/cells11091458 · Cited by 6
“It is of particular importance as a higher risk factor for Alzheimer’s disease and other neurodegenerative changes [115].”
BackgroundThe contribution of Neanderthal introgression and natural selection to neurodegenerative diseases
Chen, Z., Reynolds, R. H., Pardiñas, A. F., Taliun, S. A. G., van Rheenen, W., Lin, K., Shatunov, A., Gustavsson, E. K., Fogh, I., Jones, A. R., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106082 · Cited by 7
Self-citationVavougios, G. D., Mavridis, T., Doskas, T. K., Papaggeli, O., Foka, P., & Hadjigeorgiou, G. M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050277 · Cited by 6
“Administration of interferon beta has been shown to ameliorate glial neuroinflammation in previous studies of SARS-CoV-2 infected cells [30,57], and further research into nasal delivery of interferon beta, as well as its timing in the disease, may be warranted.”
ResultXie, Z., Li, L., Hou, W., Fan, Z., Zeng, L., He, L., Ji, Y., Zhang, J., Wang, F. J., Xing, Z., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06112-2 · Cited by 7
Huo, F., Liu, Q., Zhang, S., Liu, X., Lv, S., Zhao, M., Liu, Y., Zhu, X., Huang, C., Feng, S., et al. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01552-8 · Cited by 7
Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework
Ryan, C. B., Camargo, C. J., Salan, T., Pallikkuth, S., Gao, H., & Govind, V. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13539-6 · Cited by 7
Yang, J., Tsourdinis, G. E., Holas, C., Maienschein‐Cline, M., Lalonde, R., & Fukuchi, K.-I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1694824 · Cited by 4
“The authors of the study suggested that the increased expression of ISGs with age might help reduce age-related damage by suppressing pro-in fl ammatory signaling (79).”
Wolf, T., Moss, L. D., Hudson, C., Winters, A. M., Abdelmaboud, S. S., Avlas, M., Wohlfahrt, J., Guergues, J., Bickford, P. C., & Stevens, S. M. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70034 · Cited by 5
Multifactorial Causation of Alzheimer’s Disease Due to COVID-19
Monllor, P., Kumar, P., Lloret, M.-Á., Ftara, A., Leon, J.-L., Lopez, B., Cervera‐Ferri, A., & Lloret, A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230396 · Cited by 4
“Oligoadenylate synthetase 1 has a significant antiviral function in the immune response and very recently a genetic variant (rs1131454) was related to an increased risk of AD by its enrichment in transcriptional networks expressed by microglia [71].”
Neurocognitive Screening in Patients Following SARS-CoV-2 Infection: Tools for TriagePreprint
Blackmon, K., Day, G. S., Powers, H. R., Bosch, W., Prabhakaran, D., Woolston, D. J., & Pedraza, O. (2022) · Research Square · doi:10.21203/rs.3.rs-1127420/v1 · Cited by 4
Cell-Autonomous Immunity: From Cytosolic Sensing to Self-Defense
Han, D., Zhang, B., Wang, Z., & Mi, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094025 · Cited by 6
Zhang, M., Xie, J., Yao, S., Cai, T., Yuan, L., Liu, X., & Wang, F. W. (2025) · Scientific Reports · doi:10.1038/s41598-025-23277-4 · Cited by 3
Conformational switches in human RNA binding proteins involved in neurodegeneration
Chatterjee, S., Maity, A., & Bahadur, R. P. (2025) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2025.130760 · Cited by 4
OAS1: A Protective Mechanism for Alzheimer’s Disease? An Exploration of Data and Possible Mechanisms
Elsworthy, R. J., Pearce, A., Masoudzadeh, F., Koska, K., Lodhiya, H., Meher, G., Adjej, J., & Brookes, K. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020524 · Cited by 3
Self-citationCOVID-19 is not a causal risk for miscarriage: evidence from a Mendelian randomization study
Shi, H., Zhao, H., Zhang, W., & Wang, S. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02675-x · Cited by 5
“Another genetic variant, rs2269899, is related to the stimulatory response element 2′,5′-oligoadenylate synthase (OAS) of interferon and shows an increased expression with age [26, 27].”
BackgroundAn integrated strategy to identify COVID‐19 causal genes and characteristics represented by LRRC37A2
Zhu, Z., Chen, X., Wang, C., Zhang, S., Yu, R., Xie, Y., Yuan, S., Cheng, L., Shi, L., & Zhang, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28585 · Cited by 3
“37 To identify the tissue specificity of COVID ‐ 19, SNP ‐ based tissue enrichment analysis was focused.”
BackgroundLi, J., Tao, L., Zhou, Y., Zhu, Y., Li, C., Pan, Y., Yao, P., Qian, X., & Liu, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317915 · Cited by 3
Regulators of interferon-responsive microglia uncovered by Genome-wide CRISPRi screening
McQuade, A., Castillo, V. C., Hagan, V., Liang, W., Ta, T., Mishra, R., Teter, O. M., Gomes, L., Gonzalez, B., Teyssier, N., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00125-4 · Cited by 2
“However, microglia have been found to stronglyinduceISGsevenintheabsenceofviralinfection 10,15 – 17 .”
Ergül, Z., Kaptan, Z., Kars, A., Biçer, G., Kılınç, Ç., Petekkaya, E., & Çöplü, N. (2022) · Chemosensory Perception · doi:10.1007/s12078-022-09301-1 · Cited by 2
Sun, Q., Gao, J., An, R., Wang, M., & Wang, Y. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29590 · Cited by 2
“This bidirectional relationship is further explored by Magusali et al., 37 who uncovered a genetic connection between AD risk and severe COVID ‐ 19 outcomes, specifically through the OAS1 gene.”
BackgroundFlow Cytometry Analysis of Microglial Phenotypes in the Murine Brain During Aging and Disease
Cox, J. E. J., Pham, K. D., Keck, A. W., Wright, Z., Thomas, M. A., Freeman, W. M., & Ocañas, S. R. (2024) · BIO-PROTOCOL · doi:10.21769/bioprotoc.5018 · Cited by 3
Identifying risk factors and predicting long COVID in a Spanish cohort
Guillén-Teruel, A., Andreu, J. L. M., Reina, G., González‐Billalabeitia, E., Iborra, R. R., Palma, J. T., Botía, J. A., & Cisterna‐García, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-94765-w · Cited by 3
“Furthermore, consistent with some of these previous studies [59, 64], our research suggests that receiving two vaccine doses provides greater protection against LC-19 compared to receiving only one dose (AOR=0.38).”
InfluentialOligoadenylate synthetase 1a suppresses prion infection through binding to cellular prion protein
Homma, T., Nakagaki, T., Nishinakagawa, T., Morita, Y., Atarashi, R., Kakuta, S., Iwakura, Y., Nishida, N., & Ishibashi, D. (2025) · Brain · doi:10.1093/brain/awaf193 · Cited by 2
Li, X., Shen, Y., Xu, X., Ge, G., Chen, Y., Wei, Q., Li, H., He, K., & Liu, C. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.11.029 · Cited by 2
Wang, H., Cao, M., Xi, Y., Cao, W., Zhang, X., Meng, X., Zheng, D., Wu, L., Wang, W., Liu, D., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad198 · Cited by 2
Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk
Cohen, C. E., Fernandez, S., Yaman, U., Ehyaei, A. R., Kodosaki, E., Askarova, A., Porter, T., O’Brien, E., Study, A. I. B. A. L., Initiative, A. D. N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02036-1 · Cited by 3
“…and OAS3 ) form part of the same haplotype directly associated with AD and involved in the interferon response linked with neuroin-flammation and synapse loss in AD [59] and linked with a pro-inflammatory response via STAT/NF-kappaB in microglia/macrophages when experimentally downregulated [60].”
Self-citationThe bidirectional links between coronavirus disease 2019 and Alzheimer’s disease
Nouraeinejad, A. (2024) · International Journal of Neuroscience · doi:10.1080/00207454.2024.2327403 · Cited by 1
“In addition, genetic analysis of patients with Alzheimer’s disease and controls has recently confirmed that the oligoadenylate synthetase 1 (OAS1) variant, rs1131454, is associated with an increased risk of Alzheimer’s disease [73].”
InfluentialBalakrishnan, R., Subbarayan, R., Shrestha, R., & Chauhan, A. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11208-x · Cited by 1
“Similarly, SNPs such as rs6489867 and rs10735079 have been associated with severe COVID-19 outcomes (Magusali et al. 2021).”
InfluentialGenetic Predisposition to Neurological Complications in Patients with COVID-19
Sahajpal, N., Hastie, A. R., Schieck, M., Mondal, A. K., Felde, M., van der Made, C. I., Chou, J. S., Randolph, A. G., Illig, T., Zody, M. C., et al. (2023) · Biomolecules · doi:10.3390/biom13010133 · Cited by 1
“Moreover, these studies have remained limited to targeted gene analysis while investigating the association with neurological complications [2,3].”
Mapping cell diversity in human sporadic cerebral cavernous malformations
Hou, X., Liang, F., Li, J., Yang, Y., Wang, C., Qi, T., & Sheng, W. (2024) · Gene · doi:10.1016/j.gene.2024.148605 · Cited by 2
COVID-19 and the central nervous system: What is the interplay?
El‐Fadeal, N. M. A., Anber, S. A., Elkot, H. A., Maged, G., Saeed, I. A., Negm, M. M., Abdelsamad, M. A., El-bakri, A., & Mohamed, W. M. Y. (2022) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v5i4.155 · Cited by 1
Butusov, A. M., Krusko, O. V., Кириллович, П. П., Derevyankin, D. S., Zagranichnov, V. D., Malyshkin, S. S., & Zhurbin, E. A. (2022) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma108133
“Также показано, что две однонуклеотидные замены rs10735079(A) и rs6489867(T), которые связаны со сниженной экспрессией гена OAS1, имеют высокий уровень ассоциации с тяжелым течением COVID-19 [23].”
COVID-19 and Alzheimer's Disease, Closely Related?Preprint
Carpio-Orantes, L. D., & Reich-Sierra, R. (2023) · Qeios · doi:10.32388/7hgpuj
Brabec, J. L., Lara, M. K., Tyler, A. L., & Mahoney, J. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.03.539189 · Cited by 1
Vastrad, B. M., & Vastrad, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.02.551653 · Cited by 1
Identification of Interferon-Related Genes and Their Regulatory Mechanisms in Alzheimer's DiseasePreprint
Xie, Z., Li, L., Hou, W., Fan, Z., Zeng, L., Ji, Y., Zhang, J., Ye, Y., Wang, Y., & Xing, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4658840
New-onset seizure and acute encephalopathy
Zhang, L., Liu, X., Wu, Y., & Wang, G. (2024) · Practical Neurology · doi:10.1136/pn-2023-003994
Hutsaliuk, K., Rossokha, Z. I., Skalska, N., & Ulianova, N. A. (2024) · Oftalmologicheskii Zhurnal · doi:10.31288/oftalmolzh202415460
Chen, Y., Wang, G., Li, J., Xia, L., Zhu, L., Li, W., Luo, Q., Liao, Y., Lin, Y., Bi, L., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21376243
Chen, Y., Wang, G., Li, J., Xia, L., Zhu, L., Li, W., Luo, Q., Liao, Y., Lin, Y., Bi, L., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21376240
Li, J., Tao, L., Zhou, Y., Zhu, Y., Li, C., Pan, Y., & Liu, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4221649/v1
Metadata
- Authors
- Magusali, N., Graham, A. C., Piers, T. M., Panichnantakul, P., Yaman, U., Shoai, M., Reynolds, R. H., Botia, J. A., Brookes, K. J., Guetta-Baranes, T., Bellou, E., Bayram, S., Sokolova, D., Ryten, M., Sala Frigerio, C., Escott-Price, V., Morgan, K., Pocock, J. M., Hardy, J., & Salih, D. A.
- Affiliations
- UK Dementia Research Institute (GB)
- UCL Queen Square Institute of Neurology (GB)
- UK Dementia Research Institute at UCL, Gower Street, London WC1E 6BT, UK
- UCL Biomedical Research Centre (GB)
- Department of Neurodegenerative Diseases, Queen Square Institute of Neurology, UCL, London WC1N 1PJ, UK
- Nottingham Trent University (GB)
- Genetics, School of Life Sciences, Life Sciences Building, University Park, University of Nottingham, Nottingham NG7 2RD, UK
- Cardiff University (GB)
- Hitachi Rail Europe Ltd, New Ludgate, London EC4M 7HX, UK
- Dementia Research Institute, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff CF24 4HQ, UK
- University of Nottingham (GB)
- Corresponding author
- Salih, Dervis A
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-10-07
- Volume
- 144
- Issue
- 12
- Pages
- 3727-3741
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8500089
- OpenAlex
- W3201962999
- Cited by
- 111
- References
- 123
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 41 · 2021: 1
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Innovative Medicines Initiative 2 Joint Undertaking (115976)
- European Union's Horizon 2020
- European Federation of Pharmaceutical Industries and Associations
- Science and Technology Agency (00007/COVI/20)
- The University of Nottingham Group
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
- Alzheimer’s Research UK
- UK Medical Research Council
- Alzheimer’s Society and ARUK
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- Alzheimer's disease, COVID-19 pandemic, OAS1, genetic risk, microglia, interferon-stimulated genes, TNF-α, interferon-gamma, myeloid cells, inflammation, single nucleotide polymorphisms, induced pluripotent stem cell-derived microglia
- MeSH terms
- COVID-19, Adolescent, Aged, Aged, 80 and over, Alzheimer Disease, Cells, Cultured, Female, Humans, Genetic Linkage, Male, Middle Aged, 2',5'-Oligoadenylate Synthetase, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Gene Regulatory Networks, Young Adult, Induced Pluripotent Stem Cells, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.